Back on February 19, 2019, Ambrosia, the leading company dealing in transfusion of young blood and plasma said that the company has discontinued their treatment services. Speaking to a news reporting channel, one of the concerning figures from Ambrosia told that they had taken this step after the FDA had warned people from taking blood and plasma transfusion therapy aimed to prevent memory loss and aging.
Earlier a spokesperson of Food and Drug Administration told millions of patients that there is no evidence that infusion of blood and plasma of young person can cure Alzheimer’s, Parkinson’s or multiple sclerosis. The spokesperson of FDA also made it clear that patients who are undergoing such treatments may get prone to cardiovascular diseases, infections and various allergies. Dr. Gottlieb and Dr. Marks from FDA stated that the plasma infusion treatments have not undergone a proper clinical trial.
According to a statistical report of the federal agency, medical companies are charging a lot of fees for blood and plasma transfusion. According to the agency, Ambrosia is charging $8000 to $12000 for one and two liters of blood transfusion. Donors for the blood transfusion are basically youth who belong to age group ranging from 16 to 25 years. On the contrary, the company is targeting recipients who are older than 35 years of age.
Jesse Karmazin, the founder of Ambrosia had made many clinical trials in the past but never made any of his results public. Like one of the Stanford University, Karmazin too had advocated about the positive results of blood and plasma transfusion for a human body.
Speaking to press Dr. Sharon Sha said that she is concerned about the safety of patients who are taking plasma or blood transfusion. She further showcased her concern for the patients who are lured by various online websites to take the treatment. Dr. Sha further said that the patients who are undergoing such treatments aren’t aware of the possible risks and threats which the procedure might cause in future.